ArticleNPJ breast cancer2022

Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial.

Dou-Dou Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.